Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 80

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 80
---
, as well as forecast of continued losses and negative cash flows from operations,
raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our unaudited condensed
consolidated financial statements for the nine months ended September 30, 2025. Until we can generate sufficient revenue from the commercialization
of our product candidates, we expect to finance our operations through the public or private sale of equity, debt financing or other capital
sources, such as government funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with
third parties. Our cash and cash equivalents were $27.7 million and total current assets were $30.7 million at September 30, 2025, which
the Company is projecting will be insufficient to sustain its operations through one year following the date that the financial statements
are issued.

Additional
capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on
terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates
or cease operations. If we raise additional funds through the issuance of additional debt or equity securities it could result in dilution
to our existing stockholders, increased fixed payment obligations and these securities may have rights senior to those of our common stock
and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business,
financial condition and prospects.

Financing
strategies we may pursue include, but are not limited to, the public or private sale of equity, debt financing or funds from other capital
sources, such as government or grant funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements
with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that
it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms
acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates.
If we raise additional funds through the public or private sale of equity or